JP2022526420A5 - - Google Patents
Info
- Publication number
- JP2022526420A5 JP2022526420A5 JP2021559535A JP2021559535A JP2022526420A5 JP 2022526420 A5 JP2022526420 A5 JP 2022526420A5 JP 2021559535 A JP2021559535 A JP 2021559535A JP 2021559535 A JP2021559535 A JP 2021559535A JP 2022526420 A5 JP2022526420 A5 JP 2022526420A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- polypeptide sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962830598P | 2019-04-08 | 2019-04-08 | |
| US62/830,598 | 2019-04-08 | ||
| US201962861377P | 2019-06-14 | 2019-06-14 | |
| US62/861,377 | 2019-06-14 | ||
| US201962896790P | 2019-09-06 | 2019-09-06 | |
| US62/896,790 | 2019-09-06 | ||
| US201962928615P | 2019-10-31 | 2019-10-31 | |
| US62/928,615 | 2019-10-31 | ||
| PCT/US2020/025643 WO2020210067A1 (en) | 2019-04-08 | 2020-03-30 | Humanized anti-dll3 chimeric antigen receptors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526420A JP2022526420A (ja) | 2022-05-24 |
| JP2022526420A5 true JP2022526420A5 (enExample) | 2022-06-15 |
Family
ID=72750831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559535A Pending JP2022526420A (ja) | 2019-04-08 | 2020-03-30 | ヒト化抗ｄｌｌ３キメラ抗原受容体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220184127A1 (enExample) |
| EP (1) | EP3952888A1 (enExample) |
| JP (1) | JP2022526420A (enExample) |
| KR (1) | KR20210150432A (enExample) |
| CN (1) | CN113795262A (enExample) |
| AU (1) | AU2020271012A1 (enExample) |
| BR (1) | BR112021016272A2 (enExample) |
| CA (1) | CA3132202A1 (enExample) |
| IL (1) | IL286984A (enExample) |
| MX (1) | MX2021012336A (enExample) |
| SG (1) | SG11202108759SA (enExample) |
| WO (1) | WO2020210067A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| TWI832183B (zh) * | 2019-08-06 | 2024-02-11 | 香港商新旭生技股份有限公司 | 結合至病理性tau種類之抗體及其用途 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| US20240239878A1 (en) * | 2021-05-08 | 2024-07-18 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Binding molecule against dll3 and use thereof |
| CA3230627A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting dll3 and uses thereof |
| CN114790240B (zh) * | 2022-06-10 | 2023-06-06 | 郑州大学 | SARS-CoV-2中和性单克隆抗体及应用 |
| US20260061051A1 (en) * | 2022-08-26 | 2026-03-05 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
| CN116813784B (zh) * | 2023-05-17 | 2024-03-01 | 星奕昂(上海)生物科技有限公司 | 靶向dll3的抗体及其应用 |
| CN120731224A (zh) * | 2024-01-30 | 2025-09-30 | 石药集团巨石生物制药有限公司 | 抗dll3抗体及应用 |
| WO2025212519A1 (en) * | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2664343C (en) * | 2006-10-02 | 2016-04-26 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| CA2775573A1 (en) * | 2009-10-09 | 2011-04-14 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-her 3 antibodies |
| PL2530091T3 (pl) * | 2010-01-29 | 2018-08-31 | Chugai Seiyaku Kabushiki Kaisha | Przeciwciało przeciwko dll3 |
| CA2799746C (en) * | 2010-05-17 | 2020-11-24 | Sai Reddy | Rapid isolation of monoclonal antibodies from animals |
| WO2012019061A2 (en) * | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| JP2014529581A (ja) * | 2011-08-05 | 2014-11-13 | イフォム・フォンダツィオーネ・インスティトゥオ・フィルチ・ディ・オンコロジア・モレコラーレ | 構成的に活性なｕＰＡＲバリアントならびに阻害抗体の生成および単離へのそれの使用 |
| CN104520324A (zh) * | 2012-02-24 | 2015-04-15 | 施特姆森特Rx股份有限公司 | Dll3调节剂及其使用方法 |
| CN103173413A (zh) * | 2012-12-07 | 2013-06-26 | 天津三箭生物技术有限公司 | 小鼠抗人β-Catenin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
| GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| MX2017006167A (es) * | 2014-11-12 | 2018-03-23 | Siamab Therapeutics Inc | Compuestos que interactúan con glicanos y métodos de uso. |
| MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| BR112020005938A2 (pt) * | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
| AU2019267349B2 (en) * | 2018-05-08 | 2025-06-05 | Phanes Therapeutics, Inc. | Anti-DLL3 antibodies and uses thereof |
-
2020
- 2020-03-30 MX MX2021012336A patent/MX2021012336A/es unknown
- 2020-03-30 WO PCT/US2020/025643 patent/WO2020210067A1/en not_active Ceased
- 2020-03-30 KR KR1020217034403A patent/KR20210150432A/ko not_active Withdrawn
- 2020-03-30 SG SG11202108759S patent/SG11202108759SA/en unknown
- 2020-03-30 JP JP2021559535A patent/JP2022526420A/ja active Pending
- 2020-03-30 BR BR112021016272A patent/BR112021016272A2/pt not_active Application Discontinuation
- 2020-03-30 EP EP20788157.4A patent/EP3952888A1/en not_active Withdrawn
- 2020-03-30 US US17/593,087 patent/US20220184127A1/en not_active Abandoned
- 2020-03-30 AU AU2020271012A patent/AU2020271012A1/en not_active Abandoned
- 2020-03-30 CN CN202080027518.8A patent/CN113795262A/zh active Pending
- 2020-03-30 CA CA3132202A patent/CA3132202A1/en active Pending
-
2021
- 2021-10-05 IL IL286984A patent/IL286984A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022526841A5 (enExample) | ||
| JP2022527173A5 (enExample) | ||
| US11155615B2 (en) | Anti-ROR1 antibodies | |
| US7939072B2 (en) | Anti-EGFR antibodies with an improved anti-tumor activity and compositions and articles of manufacture comprising same | |
| JP2020501531A5 (enExample) | ||
| JP6359372B2 (ja) | ＤＡＲＰｉｎを含む二重特異キメラ蛋白質 | |
| CN103533960B (zh) | c-KIT抗体及其用途 | |
| JP2021514664A5 (enExample) | ||
| IL276830B1 (en) | Anti-claudin 18.2 antibodies and their uses | |
| JP2020528750A5 (enExample) | ||
| JP2021528047A5 (enExample) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2014531217A (ja) | ｃ−ＭｅｔのＳＥＭＡドメイン内のエピトープに特異的に結合する抗体 | |
| JP2020529863A (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| JP2024531409A5 (enExample) | ||
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| JP2018503380A5 (enExample) | ||
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2022538475A5 (enExample) | ||
| US20250388682A1 (en) | Degradation of egfr using a bispecific binding agent | |
| JP2023534959A5 (enExample) | ||
| US20250270323A1 (en) | Hhla2 binding agents with novel activity | |
| US9499622B2 (en) | Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins | |
| JP2023525991A5 (enExample) |